Video

William G. Wierda on the Treatment of CLL

Author(s):

William G. Wierda

CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.

William G. Wierda, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the treatment of chronic lymphocytic leukemia (CLL). CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals in early November.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
New Treatment Options Emerging for Across Lung Cancer Subtypes
Image of patient and doctor.
Understanding the Whole Person Behind their Cancer Diagnosis
Image of two doctors with text.
Delving Into Brain Cancer Treatment Takeaways Following ASCO 2025
image of gerds
Breaking Down the VERIFY Trial for Patients With Polycythemia Vera
Image of 2 doctors and text.
What Should Patients With Lung Cancer Know After ASCO 2025?
Image of two doctors and text.
Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025
Image of man.
A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment
Image of thumbnail.
What Patients With Genitourinary Cancers Should Know After ASCO 2025
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
How to Prepare for Self-Advocacy After a Cancer Diagnosis
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Enhertu Combo May Offer Longer Control for HER2+ Breast Cancer
Related Content
Breyanzi demonstrated a 95.5% response rate among in relapsed/refractory marginal zone lymphoma: © stock.adobe.com.
June 17th 2025

Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma

Spencer Feldman
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
After surviving prostate cancer, Andy Winnegar received a diagnosis of chronic lymphocytic leukemia (CLL) in 2021. Catch up on Andy's blogs here!
May 28th 2025

Rebuilding Resilience: Navigating Aging and Exercise After CLL

Andy Winnegar
After running the Boston Marathon at 67, I faced new limits from aging and chronic lymphocytic leukemia — but I’ve found ways to stay strong and resilient.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
image of hands.
May 17th 2025

Cancer Didn’t Break Me; It Revealed My Strength

Nicole Boyd
I’m a single mom with chronic lymphocytic leukemia sharing how cancer tested me but revealed my resilience, hardship and the power of speaking up.
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL). Read more of Chester's blogs here!
May 15th 2025

Finding Comfort in Teddy Bears Throughout My Experience With CLL

Chester Freeman
As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself.